EuCorVac-19, is a protein-based vaccine consisting of Eubiologics protein antigen, EulMT, in-licensed from Korea Institute of Science and Technology and the spontaneous-nanoliposome antigen particle (SNAP) technology of POP Biotechnologies. EuCorVac-19 has already proved its safety and efficacy in a Phase I/II clinical trial, the results of which were announced in December 2021. A Phase III clinical study is currently ongoing.